Stockscreener 앱 받기
2.23
3.46%
-0.08
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Pharmaceuticals Announces $36.9 Million Investment And Strategic Collaboration With Alpha Tau Medical - marketscreener.com
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Alpha Tau's $37M Deal Unlocks Major Growth: 4 US Trials and Marketing Alliance Signal Expansion - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Press Release Distribution & PR Platform - ACCESS Newswire
ORMPOramed Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
What To Expect From Tesla’s (TSLA) Q1 Earnings - The Globe and Mail
Oramed stock hits 52-week low at $1.95 amid market challenges - Investing.com Australia
Oramed stock hits 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Inc. (ORMP) reports earnings - qz.com
Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com
Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal
Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle
AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire
Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com
Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire
ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa
ORMP stock touches 52-week low at $2 amid market challenges - Investing.com
Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0% - Armenian Reporter
OraMed Enters Global Licensing Deal for Lidocaine Product By Investing.com - Investing.com Australia
Oramed Pharmaceuticals (ORMP) to Release Quarterly Earnings on Wednesday - MarketBeat
OraMed Enters Global Licensing Deal for Lidocaine Product - Investing.com India
Rep. Brad Knott Sells Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares - MarketBeat
Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock - Benzinga
Congress Trade: Representative Brad Knott Just Disclosed New Stock Trades - Quiver Quantitative
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to Sell Rating by StockNews.com - MarketBeat
227,239 Shares in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Acquired by Peapod Lane Capital LLC - MarketBeat
Oramed announces spinoff of protein drug technology - MSN
OraTech to pioneer oral insulin with $75 million investment - MSN
Oramed Pharmaceuticals : Ancillary Agreement Completion Protocol and Supplemental Agreement - Marketscreener.com
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St
Oramed Pharm Amends Joint Venture for OraTech Launch - TipRanks
Oramed (ORMP) Stock Skyrockets Amid JV Development Plans - Stocks Telegraph
OraTech to pioneer oral insulin with $75 million investment By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise - Marketscreener.com
Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology - Contract Pharma
Oramed stock soars on spinoff plans (ORMP:NASDAQ) - Seeking Alpha
Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin -February 11, 2025 at 09:17 am EST - Marketscreener.com
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PR Newswire
5.24%
자본화:
|
볼륨(24시간):